Acceptability and tolerability of longacting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV IMPAACT 2017MOCHA a second analysis of a phase 12 multicentre openlabel noncomparative dos

E Lowenthalj ChapmanR Ohrenschallk calabreseFaeezah PatelE et al2025-01-212025-01-21WOS2352-3018https://hdl.handle.net/10539/43570Acceptability and tolerability of longacting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV IMPAACT 2017MOCHA a second analysis of a phase 12 multicentre openlabel noncomparative dosJournal Article